Prime Medicine Inc

Prime Medicine, Inc. operates as a biotechnology company. It develops one-time curative genetic therapies, Prime Editors to address the wide spectrum of diseases by deploying its Prime Editing technology. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Gran

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Prime Medicine, Inc. (PRME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Prime Medicine, Inc. (PRME) a New Buy Stock

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter clinical development in 2024, with initial data expected in 2025 -- -- Prime Medicine Co-Founder, David Liu, Ph.D., Awarded ASGCT Outstanding Achievement Award --

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Tilray Brands

Small-cap growth stocks could be on the brink of a major trend reversal. Prime Medicine and Tilray Brands, two small-cap stocks that appear significantly undervalued, could be smart buys ahead of a potential upswing in this group of stocks.

2 Magnificent Growth Stocks With Room to Run

iRobot

Symbotic Inc

A short squeeze is a financial phenomenon where rapidly increasing prices force short sellers to buy back stocks, pushing prices even higher. This situation often arises from a large number of investors betting against a stock, anticipating its decline.

Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging

Recursion Pharmaceuticals

10X Genomics

The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime.

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?

-- Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 -- -- Progressing broader portfolio across core areas of focus; expect to initiate IND-enabling activities in first liver and ocular disease programs in 2024 --

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Instacart (Maplebear Inc.)

Exelixis

Gates Industrial

Iovance Biotherapeutics

Public offerings of stock tempted some insiders, including a chief executive, to increase their stakes in a couple of biotechs and an industrial products maker.

Stock Offerings Prompt Big Insider Buying

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten upsized public offering of 22,560,001 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten upsized public offering of 19,200,001 shares of its common stock at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 3,360,000 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $140.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares and pre-funded warrants in the offering are to be sold by Prime Medicine. The offering is expected to close on or about February 20, 2024, subject to satisfaction of customary closing conditions.

Prime Medicine Announces Pricing of Upsized Public Offering

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares of common stock in the proposed offering are to be sold by Prime Medicine. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Prime Medicine Announces Proposed Public Offering of Common Stock

Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating its commitment to innovation and belief in its technology. Despite financial losses, Prime Medicine maintains a strong cash position, providing stability and flexibility for future growth.

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the Company with up to $15 million to support the development of Prime Editors for the treatment of Cystic Fibrosis (CF).

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced that it will provide up to $15 million to Prime Medicine for preclinical research into gene editing for cystic fibrosis. Prime Medicine is using a gene editing technology called prime editing — a technology that enables insertions or deletions of small segments of DNA at precise sites. Prime Medicine — founded by researchers who pioneered the development of this unique editing technology — is investigating whether p.

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

The mean of analysts' price targets for Prime Medicine, Inc. (PRME) points to an 111.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know

CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company's Chief Financial Officer, effective January 17, 2024. A seasoned financial executive with over twenty years' experience in the biotechnology industry, Dr. Reine will be responsible for the company's financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company.

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 2:15 p.m. PT (5:15 p.m. ET) in San Francisco, CA.

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Archer Aviation

Small-cap growth stocks might be gearing up for a strong showing in 2024. Archer Aviation and Prime Medicine might benefit from a trend reversal in this segment of the market.

Better Growth Stock: Archer Aviation or Prime Medicine?

ARK Genomic Revolution Multi-Sector ETF

Beam Therapeutics

Caribou Biosciences

CRISPR Therapeutics

Editas Medicine

Robinhood

Eli Lilly

Intellia Therapeutics

Regeneron Pharmaceuticals

Verve Therapeutics

Vertex Pharmaceuticals

Genomic medicine is predicted to become a multi-billion-dollar industry. Even so, this market will probably take years to mature, and risks abound as a result.

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

AI isn't just revolutionizing biotech; it's reinventing it. From predicting diseases to accelerating drug discovery, AI is turning data into medical gold, reshaping how we approach healthcare innovation. AI is turbocharging techniques like CRISPR and Prime Editing, opening doors to previously unimaginable genetic breakthroughs. In the AI-enhanced biotech arena, traditional valuation metrics are old news. Speed, efficiency, and the ability to leapfrog development stages redefine how we value these trailblazing firms.

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

Cathie Wood is known for investing in cutting-edge innovators. Her ARK Genomic Revolution ETF owns several gene-editing companies, but Prime Medicine might be the best of the bunch.

1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years

Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that company management will present at two upcoming investor conferences:

Prime Medicine to Present at Upcoming Investor Conferences

-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of lead Prime Editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile --

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Up to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well Above Anticipated Threshold Necessary to Reverse Disease Manifestations

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

News for Prime Medicine Inc Stock (PRME)